Skip to main content
Equibles

Tina Ventura

Head of Investor Relations

Madrigal Pharmaceuticals, Inc. (MDGL)

Equibles does not estimate personal net worth.

Get an email with a short summary when Madrigal Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.

Get MDGL alerts

About Tina Ventura

Tina Ventura is recorded as Head of Investor Relations at Madrigal Pharmaceuticals, Inc. (MDGL). Tina Ventura has spoken on 9 earnings calls across 1 company, most recently for Madrigal Pharmaceuticals, Inc. on November 3, 2026. Madrigal Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Madrigal Pharmaceuticals, Inc. includes Bill Sibold (CEO and Board Member), Julian C. Baker (Chairman and Board Member), Mardi Dier (CFO) and 7 others.

Tina Ventura on recent calls

“Good morning, everyone, and thank you for joining us to discuss Madrigal's third quarter 2026 results. We issued a press release this morning and posted a slide deck to accompany this webcast on the Investor Relations section of our website.”
Head of Investor Relations, Q3 2026 Earnings Call ·
“Good morning, everyone, and thank you for joining us to discuss Madrigal's second quarter 2026 results. We issued a press release this morning and posted a slide deck to accompany this webcast on the Investor Relations section of our website.”
Head of Investor Relations, Q2 2026 Earnings Call ·
“Good morning, everyone, and thank you for joining us to discuss Madrigal's first quarter 2026 earnings. We issued a press release this morning and posted a slide deck to accompany this webcast on the Investor Relations section of our website.”
Head of Investor Relations, Madrigal Pharmaceuticals, Inc. Q1 FY2026 Earnings Call ·
“Good morning, everyone, and thank you for joining us to discuss Madrigal's fourth quarter and full year 2025 earnings. We issued a press release this morning and posted a slide deck to accompany this webcast on the Investor Relations section of our website.”
Head of Investor Relations, Madrigal Pharmaceuticals, Inc. Q4 FY2025 Earnings Call ·
“Good morning, everyone, and thank you for joining us to discuss Madrigal's third quarter 2025 earnings. We issued a press release this morning and posted a slide deck that accompanies this webcast on the Investor Relations section of our website.”
Head of Investor Relations, Madrigal Pharmaceuticals, Inc. Q3 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at Madrigal Pharmaceuticals, Inc.

Recent activity